{"type":"trials","record":{"id":41524,"source_id":"clinicaltrials-gov","external_id":"NCT05536297","title":"Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy","brief_summary":"The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 23 visit on study treatment (either avacincaptad pegol or Sham).","overall_status":"Completed","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Astellas Pharma Global Development, Inc.","enrollment":278,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Colombia","Croatia","Czechia","France","Germany","Hungary","Israel","Italy","Latvia","Spain"],"start_date":"2022-09-26","completion_date":"2025-04-10","last_update_date":"2026-05-18","source_url":"https://clinicaltrials.gov/study/NCT05536297","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Astellas Pharma Inc","interventions":["avacincaptad pegol"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Participants With Adverse Events (AEs) — Up to 18 months","Number of Participants With Anti-drug Antibody (ADA) — Up to 18 months","Plasma Concentrations of ACP — Months 1, 2, 4, 7, 13, and 18"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Geographic Atrophy","Age-Related Macular Degeneration","avacincaptad pegol"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05536297","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2022-09-26 to 2025-04-10","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.827Z","intervention":["avacincaptad pegol"],"participants":278,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Participants With Adverse Events (AEs) — Up to 18 months","Number of Participants With Anti-drug Antibody (ADA) — Up to 18 months","Plasma Concentrations of ACP — Months 1, 2, 4, 7, 13, and 18"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41524","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}